PulseAugur / Brief
EN
LIVE 14:08:22

Brief

last 24h
[2/2] 223 sources

Multi-source AI news clustered, deduplicated, and scored 0–100 across authority, cluster strength, headline signal, and time decay.

  1. TOOL · MIT Technology Review English(EN) · · [2 sources]

    David Sinclair plans to test whole-body rejuvenation drugs in the XPrize competition

    Longevity scientist David Sinclair is preparing to test an oral drug mixture, code-named SL-100, designed for whole-body rejuvenation. These human trials are intended to compete in the XPrize Foundation's Healthspan Competition, which offers a $101 million prize for teams demonstrating a significant reversal of apparent age. The approach uses chemical reprogramming to reset epigenetic marks, aiming for broader effects than previous gene therapy trials. AI

    IMPACT This research could lead to new therapeutic approaches for aging, potentially impacting healthcare and life extension industries.

  2. COMMENTARY · MIT Technology Review English(EN) · · [2 sources]

    The Download: whole-body rejuvenation drugs and five things to know about AI

    MIT Technology Review's daily newsletter, The Download, covers significant developments in AI and longevity research. The publication highlights OpenAI's confidential filing for a US IPO, potentially valuing the company at $1 trillion and testing investor interest in AI firms. Additionally, it discusses longevity scientist David Sinclair's plans to initiate human trials for a "reprogramming" drug aimed at age restoration, as part of an XPrize competition. AI

    The Download: whole-body rejuvenation drugs and five things to know about AI

    IMPACT OpenAI's potential IPO could significantly impact AI investment trends and market valuations.